Ocular Therapeutix (OCUL) Assets (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Assets of $671.3 million for Q2 2026, up 48.74% year-over-year from $451.3 million in Q2 2025, and down 8.36% on a QoQ basis from $732.5 million in Q1 2026.
Ocular Therapeutix (OCUL) Assets (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Assets for 14 years, with the latest figure at $671.3 million in Q2 2026.
- Assets for Q2 2026 came in at $671.3 million, up 48.74% year-over-year; the trailing twelve-month figure through Jun 2026 was $671.3 million (up 48.74% YoY), and the FY2025 annual result was $808.1 million, up 76.46% from the prior year.
- Assets fell to $671.3 million in Q2 2026, from $732.5 million in the prior quarter.
- Over five years, Assets peaked at $808.1 million in Q4 2025 and troughed at $122.6 million in Q2 2023.
- A 5-year average of $378.8 million and a median of $408.4 million in 2025 frame the typical range for Assets.
- The widest annual swing landed in 2023, when Assets tumbled 31.47%; it then soared 321.92% in 2024.
- A 5-year view of Assets shows it stood at $149.3 million in 2022, then surged by 68.84% to $252.1 million in 2023, then jumped by 81.68% to $457.9 million in 2024, then soared by 76.46% to $808.1 million in 2025, then slipped by 16.92% to $671.3 million in 2026.
- Per Business Quant data, the three most recent Assets figures were $671.3 million in Q2 2026, $732.5 million in Q1 2026, and $808.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 671.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 671.32 Mn |
| Mar 31, 2026 | 732.53 Mn |
| Dec 31, 2025 | 808.06 Mn |
| Sep 30, 2025 | 410.88 Mn |
| Jun 30, 2025 | 451.33 Mn |
| Mar 31, 2025 | 405.92 Mn |
| Dec 31, 2024 | 457.94 Mn |
| Sep 30, 2024 | 490.37 Mn |
| Jun 30, 2024 | 517.09 Mn |
| Mar 31, 2024 | 538.95 Mn |
| Dec 31, 2023 | 252.06 Mn |
| Sep 30, 2023 | 162.38 Mn |
| Jun 30, 2023 | 122.56 Mn |
| Mar 31, 2023 | 128.57 Mn |
| Dec 31, 2022 | 149.29 Mn |
| Sep 30, 2022 | 158.58 Mn |
| Jun 30, 2022 | 173.07 Mn |
| Mar 31, 2022 | 187.62 Mn |
| Dec 31, 2021 | 204.89 Mn |
| Sep 30, 2021 | 217.74 Mn |